Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 7/20 | 0.53 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.46 |
| ▸ | SMO | Q99835 | 3/20 | 0.44 |
| ▸ | MTTP | P55157 | 1/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
| ▸ | RHOC | P08134 | 1/20 | 0.41 |
| ▸ | RHOA | P61586 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22556320 | 1.00 | RXFP1 (0.53) | RXFP1TRPV1SMOMTTPMAPK8 | |
| SCHEMBL30463796 | 0.87 | KMT2A (0.51) | RXFP1 | |
| SCHEMBL23701612 | 0.80 | RXFP1 (0.50) | RXFP1TRPV1SMOMAPK8RHOC | |
| SCHEMBL22556334 | 0.77 | RXFP1 (0.53) | RXFP1MAPK8GAATDP1 | |
| SCHEMBL29888333 | 0.75 | RXFP1 (0.48) | RXFP1SMO | |
| SCHEMBL22571443 | 0.75 | GAA (0.57) | RXFP1GAATDP1 | |
| SCHEMBL22556321 | 0.73 | RXFP1 (0.53) | RXFP1MAPK8 | |
| SCHEMBL4245559 | 0.73 | MAPK8 (0.67) | RXFP1MAPK8 | |
| SCHEMBL23713156 | 0.73 | RXFP1 (0.47) | RXFP1MAPK8 | |
| SCHEMBL22556306 | 0.73 | RXFP1 (0.53) | RXFP1MAPK8GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11661403-B2 | Oxadiazole compounds | VIVACE THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-20210238154-A1 | OXADIAZOLE COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238154-A1 | OXADIAZOLE COMPOUNDS | YAP1, TEAD2, TEAD3 | RXFP1 3511/4885TRPV1 4341/4885SMO 313/4885 |
| US-11661403-B2 | Oxadiazole compounds | YAP1, TEAD2, TEAD3 | RXFP1 3511/4885TRPV1 4341/4885SMO 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.